HHBT.US HH Biotechnology Holdings Company
- Market cap
- USD 1.41K
- P/E
- -
- P/B
- 0.26x
- ROE
- 8.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2016.
Is HHBT.US undervalued?
Graham numberThe Graham number of HH Biotechnology Holdings Company cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HH Biotechnology Holdings Company fundamental analysis
No fundamental analysis for HH Biotechnology Holdings Company yet.
HH Biotechnology Holdings Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HH Biotechnology Holdings Company
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorporated in 1987 and is headquartered in Shenyang, the People's Republic of China.
Full company profileHH Biotechnology Holdings Company financial statements
2016 annualized: Fiscal year 2016 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2016, the balance sheet is the latest quarter. Figures change when the annual report is published.
HH Biotechnology Holdings Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 7.35M | 7.69M | 7.99M | 7.99M | 7.61M |
| Gross Profit | 1.06M | 1.24M | 1.70M | 2.35M | 2.73M |
| Operating Income | -914K | -656K | -2.77M | 3.10M | 3.51M |
| EBITDA | - | - | - | 6.75M | - |
| Net Income | -2.33M | -1.81M | -4.31M | 2.48M | 2.65M |
| EPS | - | - | - | 0.18 | 0.19 |
| Balance Sheet | |||||
| Total Assets | 59.4M | 59.6M | 54.0M | 46.5M | 42.8M |
| Total Liabilities | 34.3M | 35.5M | 34.8M | 18.1M | 13.2M |
| Shareholders' Equity | 25.1M | 24.0M | 19.1M | 28.2M | 29.6M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 9.82M | 0.00 |
| Total Debt | - | - | - | 4.63M | - |
| Cash Flow | |||||
| Operating Cash Flow | 766K | 1.69M | 1.69M | 3.57M | 4.78M |
| Capital Expenditure | 0.00 | 67.56 | 0.85 | 41.9K | 19.49 |
| Free Cash Flow | - | - | - | 3.53M | - |
| Ratios | |||||
| ROE | -9.3% | -7.6% | -22.5% | 8.8% | 8.9% |
| ROA | -3.9% | -3.0% | -8.0% | 5.3% | 6.2% |
| Net Profit Margin | -31.6% | -23.6% | -54.0% | 31.0% | 34.8% |
| Debt to Equity | - | - | - | 0.16x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HH Biotechnology Holdings Company dividends
HH Biotechnology Holdings Company has not paid dividends in the last 4 fiscal years.
Who owns HH Biotechnology Holdings Company
- Insiders 80.77%
- Institutions 0.00%
- Public & others 19.23%
- Shares outstanding 14.1M
- Free float 2.70M
HH Biotechnology Holdings Company company profile
- Company name
- HH Biotechnology Holdings Company
- Ticker
- HHBT.US
- Exchange
- USA Stocks
- Sector
- Real Estate
- Industry
- Real Estate Management & Development
- Employees
- 121
- Fiscal year end
- December
- Address
- President Building, Shenyang, China, 110003
- Phone
- 86 24 2281 3888
- Website
- greatchinaholdings.com
About HH Biotechnology Holdings Company
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorporated in 1987 and is headquartered in Shenyang, the People's Republic of China.
HH Biotechnology Holdings Company management
5- Mr. Sheng JiangChief Executive Officer and Director
- Ms. Li Rong WangChief Financial Officer · born 1963
- Liang ZouVice President of Operations
- Mr. Yee Kwa TangInvestor Relations Officer
- Sasaki KojiVice President of Marketing